Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JAB-8263 in advanced malignant tumors
NCT04686682Phase 2Recruiting
- Sponsor
- Jacobio Pharmaceuticals
- Start
- May 2021
- Primary completion
- Jan 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of jab-8263 in non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), castration-resistant prostate cancer (CRPC), Esophageal Squamous Cell Carcinoma (ESCC), ovarian carcinoma, sponsored by Jacobio Pharmaceuticals. Started May 2021; status: recruiting.
02
Drugs
jab-8263
03
Conditions
non-small cell lung cancer (NSCLC)small cell lung cancer (SCLC)castration-resistant prostate cancer (CRPC)Esophageal Squamous Cell Carcinoma (ESCC)ovarian carcinoma
Beyond the preview
Go deeper on NCT04686682.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04686682.